NUFORMIX PLC Logo

NUFORMIX PLC

Pharmaceutical developer using cocrystal technology to repurpose drugs for fibrosis.

NFX | IL

Overview

Corporate Details

ISIN(s):
GB00BYW79Y38
LEI:
2138003XG3H3I2J3BJ24
Country:
United Kingdom
Address:
6TH FLOOR, EC3V 0HR LONDON

Description

Nuformix PLC is a pharmaceutical development company focused on drug repurposing to address unmet medical needs, particularly in fibrosis and oncology. The company utilizes its expertise in cocrystal technology to unlock the therapeutic potential of approved drugs. This strategy involves creating new solid forms of existing medicines to improve their physical properties and performance, aiming to develop novel treatments with potentially accelerated development timelines.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-01-13 08:00
NXP002 Orphan Drug Designation Draft Application
English 9.6 KB
2024-11-29 18:00
Total Voting Rights
English 9.1 KB
2024-11-05 15:25
Director/PDMR Dealings
English 39.9 KB
2024-11-04 11:17
Result of General Meeting
English 21.2 KB
2024-10-18 11:34
Nuformix plc - Single prospectus
English 1.6 MB
2024-10-16 14:37
Publication of Prospectus & Notice of GM
English 16.4 KB
2024-09-20 15:24
£300,000 Fundraise
English 21.4 KB
2024-06-18 08:00
Half-year Report
English 199.8 KB
2024-06-17 08:00
Patent Update
English 13.0 KB
2024-03-19 15:39
Result of AGM
English 27.1 KB
2024-03-01 08:00
Subscription to raise £150,000
English 11.5 KB
2024-01-15 12:30
Posting of Annual Report and Notice of AGM
English 11.2 KB
2024-01-03 08:00
Results for the period ended 30 September 2023
English 423.9 KB
2023-12-18 08:00
NXP001 Update
English 10.5 KB
2023-10-23 08:00
Notice of Allowance of NXP002 Patent in Japan
English 11.0 KB

Automate Your Workflow. Get a real-time feed of all NUFORMIX PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NUFORMIX PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NUFORMIX PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.